The changing scene of adult acute lymphoblastic leukemia

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 652-659

  Vitale, Antonella ^a   Guarini, Anna ^a   Chiaretti, Sabina ^a   Foà, Robin ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Institute of Hematology   (Italy)

Author keywords

Adult acute lymphoblastic leukemia; Diagnosis; Prognosis; Therapy

Indexed keywords

ALEMTUZUMAB; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ASPARAGINASE MACROGOL; BCR ABL PROTEIN; CLOFARABINE; CYTARABINE; DASATINIB; DAUNORUBICIN; EPRATUZUMAB; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; IMATINIB; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; NELARABINE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CYTOGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

ADULT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 33748909536     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245317.82391.1b     Document Type: Review

References (104)

1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350:1535-1548.
2. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005; 23:6306-6315. This review reports some of the more recent findings delineating the molecular genetics of ALL.
3. Redaelli A, Laskin BL, Stephens JM, et al. A systematic literature review of the clinical and epidemiological burden of acute lymphoblastic leukaemia (ALL). Eur J Cancer Care 2005; 14:53-62. The authors summarize the published literature about the clinical and epidemiological questions of ALL.
4. Gao F, Nordin P, Krantz I, et al. Variation in the seasonal diagnosis of acute lymphoblastic leukemia: evidence from Singapore, the United States, and Sweden. Am J Epidemiol 2005; 162:753-763.
5. Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol 2004; 50:223-261.
6. Randolf TR. Advances in acute lymphoblastic leukemia. Clin Lab Sci 2004; 17:235-245.
7. Ferrando AA, Look AT. DNA microarrays in the diagnosis and management of acute lymphoblastic leukemia. Int J Hematol 2004; 80:395-400.
8. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-838.
9. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005; 80:1517-1527.
10. Foà R, Vitale A. Towards an integrated classification of adult acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002; 6:181-199.
11. Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 2002; 6:114-141.
12. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33:451-458.
13. Harris NI, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
14. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85:1416-1434.
15. Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004; 112:8-15.
16. Ciudad J, San Miguel JF, Lopez-Berges MC, et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16:3774-3781.
17. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 1999; 93:3931-3939.
18. Vidriales MB, San Miguel JF, Orfao A, et al. Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 2003; 16:599-612.
19. Bene MC. Immunophenotyping of acute leukemias. Immunol Lett 2005; 98:9-21. This review reports the current state of the art of immunophenotyping of ALL and discusses its clinical relevance.
20. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9:1783-1786.
21. Nemecek ER, Matthews DC. Antibody-based therapy of human leukemia. Curr Opin Hematol 2002; 9:316-321.
22. Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004; 83:201-205.
23. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996; 87:3135-3142.
24. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999; 93:3983-3993.
25. Harrison CJ, Foroni L. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002; 6:91-113.
26. Ferrando AA, Look AT. Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. Semin Hematol 2000; 37:381-395.
27. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood 2005; 105:3434-3441. In this report the authors highlight the importance of a combined cytogenetic-molecular profiling of adult ALL at diagnosis.
28. Elia L, Mancini M, Moleti L, et al. A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. Haematologica 2003; 88:275-279.
29. Van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17:2257-2317.
30. Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet 2005; 6:782-792. This study refers to the advanced techniques that are changing the role of cytogenetics in both basic research and molecular diagnosis.
31. Tafuri A, Gregorj C, Petrucci MT, et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002; 100:974-981.
32. Ferguson LR, Flora SD. Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 2005; 591:24-33.
33. Plasschaert SL, de Bont ES, Boezen M, et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005; 11:8661-8668. The study shows that a subset of ALL patients with high multidrug-resistance associated protein expression has an unfavorable prognosis independently of age.
34. Jamroziak K, Balcerczak E, Cebula B, et al. Multidrug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep 2005; 57:882-888.
35. Swerts K, De Moerloose B, Dhooge C, et al. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer 2006; 42:295-309.
36. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531-537.
37. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1:75-87.
38. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133-143.
39. Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood 2004; 104:923-932.
40. Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004; 103:2771-2778.
41. Chiaretti S, Li X, Gentleman R, et al. Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res 2005; 11:7209-7219. This study shows that genomic signatures are associated with phenotypically and molecularly defined subgroups of adult ALL and identifies genes associated with poor outcome in cases without molecular aberrations.
42. Haferlach T, Kohlmann A, Schnittger S, et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 2005; 106:1189-1198.
43. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood 2004; 103:1043-1049.
44. Brown P, Levis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105:812-820.
45. Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20:1094-1104.
46. Foroni L, Hoffbrand AV. Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002; 15:71-90.
47. Gokbuget N, Kneba M, Raff T, et al. Risk-adapted treatment according to minimal residual disease in adult ALL. Best Pract Res Clin Haematol 2002; 15:639-652.
48. Bruggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116-1123. This study shows that MRD quantification during treatment identifies prognostic subgroups within adult patients with standard-risk ALL who benefit from individualized treatment.
49. Toubai T, Tanaka J, Ota S, et al. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients. Am J Hematol 2005; 80:181-187.
50. Van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ. Detection of minimal residual disease in acute leukemia. J Biol Regul Homeost Agents 2004; 18:146-154.
51. Vidriales MB, Perez JJ, Lopez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101:4695-4700.
52. Krampera M, Vitale A, Vincenzi C, et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol 2003; 120:74-79.
53. Elia L, Gottardi E, Floriddia G, et al. Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. Leukemia 2004; 18:1824-1830.
54. Pane F, Cimino G, Izzo B, et al. Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005; 19:628-635.
55. Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements. Haematologica 2002; 87:1126-1134.
56. Bruggemann M, van der Velden VH, Raff T, et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 2004; 18:709-719.
57. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99:1536-1543.
58. Asnafi V, Buzyn A, Thomas X, et al. Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study. Blood 2005; 105:3072-3078. The authors report that both TCR and genotypic stratification can contribute to risk-adapted management of adult T-ALL.
59. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am 2000; 14:1367-1379.
60. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547-561.
61. Kantarjian HM, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukaemia. Cancer 2004; 101:2788-2801.
62. Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99:863-871.
63. Gokbuget N, Raff R, Brugge-Mann M, et al. Risk/MRD adapted GMALL trials in adult ALL. Ann Hematol 2004; 83 (Suppl 1):S129-S131.
64. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22:4075-4086.
65. Rowe JM, Buch G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005; 106:3760-3767. This report validates several previously identified prognostic factors in ALL, such as age, white blood cell count, immunophenotype, cytogenetics and molecular biology.
66. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-178. This report represents a complete and detailed review of different modalities of treatment for children and adults with ALL.
67. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995; 86:2091-2097.
68. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis. Results from the International ALL Trial MRC UKALL-XII/ECOG E2993. Blood 2006, Mar 23 [Epub ahead of print].
69. Sancho JM, Ribera JM, Oriol A, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer 2006. May 12 [Epub ahead of print].
70. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104:3028-3037.
71. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as postremission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005; 90:1346-1356.
72. Dhedin N, Dombret H, Thomas X, et al. Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85-87 and -94 trials. Leukemia 2006; 20:336-344.
73. Mato AR, Luger SM. Autologous stem cell transplant in ALL: who should we be transplanting in first remission? Bone Marrow Transplant 2006; 37:989-995.
74. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant 2006; 12:1-30. This comprehensive and systematic review presents and critically evaluates the role of hematopoietic SCT in the treatment of adult ALL.
75. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276-2285.
76. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351:2265-2275.
77. Sawyers C. Targeted cancer therapy. Nature 2004; 432:294-297.
78. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6:117-129.
79. Wassmann B, Gokbuget N, Scheuring UJ, et al. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10). Ann Hematol 2003; 82:716-720.
80. Lee S, Kim YJ, Min CK, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105:3449-3457.
81. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24:460-466. The authors report on the efficacy and feasibility of chemotherapy combined with imatinib for BCR-ABL ALL.
82. Vignetti M, Fazi P, Meloni G, et al. Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201. Blood 2004; 104:749a; Abstract.
83. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401.
84. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-4505.
85. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-481.
86. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells. Blood 2006, Mar 14 [Epub ahead of print].
87. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542-2551. First clinical study that reported the response to nilotinib in Ph+ ALL patients who are resistant to imatinib treatment.
88. Talpaz S, Shah NP, Kantajian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-2541. First clinical study describing the results of desatinib use in imatinib resistant Ph+ALL.
89. Cortes J, Faderl S, Estey E, et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 2005; 23:2805-2812.
90. Torelli GF, Guarini A, Porzia A, et al. FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. Br J Haematol 2005; 130:43-50.
91. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003; 123:836-841.
92. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004; 22:3916-3921.
93. Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer 2005; 103:1985-1995.
94. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105:940-947.
95. Kline JP, Larson RA. Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opin Pharmacother 2005; 6:2711-2718.
96. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23:3396-3403.
97. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106:376-383.
98. Van Driessche A, Gao L, Stauss HJ, et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19:1863-1871.
99. Stock W, Sather H, Dodge RK, et al. Outcome of adolescents and young adults with ALL: A comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens. Blood 2000; 96:467a; Abstract.
100. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21:774-780.
101. De Bont JM, van der Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18:2032-2053.
102. Testi AM, Valsecchi MG, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) multicenter protocols. Blood 2004; 104:539a; Abstract.
103. Nachman J. Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 2005; 130:166-173. This report represents a complete and detailed review of different treatment modalities for young adult ALL patients.
104. Schiffer CA. Difference in outcome in adolecent with acute lymphoblastic leukemia: a consequence of better regimes? Better doctors? Both? J Clinic Oncol 2003; 21:760-761.